AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data
AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus either carboplatin or cisplatin.
The Imfinzi-chemotherapy demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
The data show the longest survival update ever reported for immunotherapy treatment in this setting, the Company says.
The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.
The latest results for IMFINZI plus chemotherapy showed sustained efficacy after a median follow-up of more than three years, with a 29% reduction in the risk of death versus chemotherapy alone.
Updated median OS was 12.9 months versus 10.5 for chemotherapy.
The results included a planned exploratory analysis, where an estimated 17.6% of patients treated with IMFINZI plus chemotherapy were alive at three years, versus 5.8% of patients treated with chemotherapy alone.
Results showed that 32.5% of patients experienced a serious adverse event (all causality) with Imfinzi/chemo versus 36.5% with chemotherapy alone.
Price Action: AZN stock is up 4.51% at $58.06 during the market session on the last check Monday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
